A patient may be a candidate for GLP-1 injections if they are struggling with weight loss, appetite control, overeating, cravings, obesity, or weight-related health concerns
The bi-phasic life cycle of the Bacillus spores allows them to remain dormant in harsh environments until they reach more favorable environments like the human gastrointestinal tract
3 Evolution of GLP-1-based therapeutics 3.1 First-generation GLP-1RAs The development of GLP-1 receptor agonists stemmed from the significant finding that natural GLP-1 had an exceptionally short half-life of about 1.5 to 5 min, due to its rapid degradation by the enzyme DPP-4 (Campbell and Drucker 2013) (Fig
Users who rely solely on the medication for weight reduction risk a condition sometimes referred to as "sarcopenic obesity," where weight is low or normal, but muscle mass is dangerously insufficient
administering bacteriostatic water alone or in excessive volume could result in serious complications (such as hemolysis or fluid imbalance)
[6] [7] These medications work by mimicking the action of the naturally occurring incretin hormone GLP-1, which is released from the intestine in response to food intake